SCHEMBL4709684

SCHEMBL4709684

CCOC(=O)c1ccc(/C=C/c2cc3c(cc2Cn2cccn2)C(C)(C)C(OC(C)=O)CC3(C)C)cc1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RARA P10276 5/20 0.34
RARB P10826 5/20 0.34
RARG P13631 2/20 0.34
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PPARG P37231 1/20 0.31
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
NPSR1 Q6W5P4 3/20 0.31
GAA P10253 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KLKB1 P03952 1/20 0.31
HDAC1 Q13547 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
SNCA P37840 1/20 0.30
ENPP2 Q13822 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4709687 0.85 MAPT (0.34) RARARARBRARGMAPTALDH1A1
SCHEMBL4710151 0.85 RARA (0.38) RARARARBRARGMAPTALDH1A1
SCHEMBL4712702 0.83 RARA (0.50) RARARARBRARGALDH1A1LMNA
SCHEMBL14159920 0.82 RARA (0.36) RARARARBRARGMAPTALDH1A1
SCHEMBL4713008 0.82 HDAC1 (0.35) RARARARBRARGMAPTALDH1A1
SCHEMBL4713010 0.82 HDAC1 (0.35) RARARARBRARGMAPTALDH1A1
SCHEMBL14159950 0.80 RARA (0.34) RARARARBRARGALDH1A1
SCHEMBL4711960 0.79 RARA (0.46) RARARARBRARGMAPTALDH1A1
SCHEMBL4711107 0.79 RARA (0.46) RARARARBRARGMAPTALDH1A1
SCHEMBL4711109 0.79 RARA (0.46) RARARARBRARGMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1935869-A1 Retinoids for the treatment of emphysema F. HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
US-6777418-B2 FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-08-17 US disclosed
EP-1324970-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 EP disclosed
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders SYNTEX (U.S.A.) LLC 2002-06-27 US disclosed
WO-2002028810-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders RXRA, RXRG, RXRB RARA 5/4885RARB 6/4885RARG 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.